Zenlabs Ethica Limited reported a substantial net loss of ₹200.76 lakhs for the third quarter of FY26 ended December 31, 2025, marking a significant reversal from the profit of ₹8.51 lakhs recorded in the corresponding quarter of the previous year. The loss was primarily driven by exceptional charges related to the company's exit from its Non-Banking Financial Company (NBFC) operations following regulatory action by the Reserve Bank of India.

Financial Performance Overview

The company's financial performance for Q3FY26 reflected the impact of regulatory changes and business realignment:

NBFC Registration Cancellation Impact

The company faced a major regulatory setback when the Reserve Bank of India cancelled its NBFC registration certificate on November 7, 2025, under Section 45-IA of the RBI Act, 1934. This regulatory action prohibited the company from continuing its NBFC activities, necessitating a complete business model realignment.

As a result of this development, Zenlabs Ethica disposed of and wrote off investments and other loans and advances that were no longer consistent with its permitted operations. The financial impact of ₹207.81 lakhs from these disposals and write-offs was classified as an exceptional item in Q3FY26.

Leadership Appointments

The Board of Directors approved the appointment of Amit Kumar as Company Secretary and Compliance Officer effective February 7, 2026. This appointment was made to fulfill the requirements of Section 203 of the Companies Act, 2013, and Regulation 6(1) of the SEBI Listing Regulations.

Amit Kumar brings relevant qualifications to the role, being an Associate member of the Institute of Company Secretaries of India. His remuneration and other terms of appointment will be governed by the Nomination and Remuneration Committee and the Board of Directors.

Nine-Month Performance

For the nine months ended December 31, 2025, the company reported:

Current Business Focus

Following the NBFC registration cancellation, Zenlabs Ethica continues to operate as a single-segment company engaged in the trading of pharmaceutical formulations. The company maintains its registered office in Chandigarh and continues its pharmaceutical trading operations while adapting to the regulatory changes that have eliminated its financial services activities.

The Board of Directors approved these developments in their meeting held on February 7, 2026, with the statutory auditors N Kumar Chhabra and Co. providing an unmodified opinion in their limited review report on the financial results.

Zenlabs Ethica Limited has announced a significant change in its key managerial personnel. Ms. Manju Bala, the Company Secretary and Compliance Officer, has tendered her resignation, citing a better opportunity at another organization.

Key Details of the Resignation

Impact and Company Response

The resignation of Ms. Bala will take effect from the close of business hours on December 04, 2025. This change affects the key managerial personnel structure of Zenlabs Ethica Limited.

The Board of Directors has acknowledged Ms. Bala's contribution, expressing their appreciation for the valuable services she rendered during her tenure with the company.

Compliance and Next Steps

Zenlabs Ethica Limited has made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company will need to file the necessary forms with the Registrar of Companies, Chandigarh, to give effect to this change.

As per regulatory requirements, Ms. Bala has confirmed that there are no other material reasons for her resignation other than those mentioned in her resignation letter.

The company has not yet announced a replacement for the position of Company Secretary and Compliance Officer.

This development underscores the importance of key managerial personnel in maintaining regulatory compliance and smooth operations in listed companies.